Centre Hospitalier de Cornouaille
Centre Hospitalier de Cornouaille
Quimper, France6 results ยท Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Study Evaluating Combination of Luspatercept in LR-MDS Without RS Having Failed or Being Ineligible to ESA | Hemic and Lymphatic Diseases, bone marrow disorder, hematologic disorder, myelodysplastic syndrome | Recruiting | Phase 1 / Phase 2 | 2026-09-29 | NCT05181735 | |
| MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide) | Blood Protein Disorders, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, cardiovascular disorder, hematologic disorder, hemorrhagic disease, immune system disorder, immunoproliferative disorder, lymphoproliferative syndrome, monoclonal gammopathy, neoplasm, plasma cell neoplasm, vascular disorder, vascular hemostatic disease | Recruiting | Phase 3 | 2026-08-24 | NCT06152575 | |
| Pembrolizumab and Chemotherapy Treatment or no Treatment Guided by the Level of TILs in Resected Early-stage TNBC | Neoplasms by Site, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, neoplasm, skin disorder, triple-negative breast carcinoma | Recruiting | Phase 2 | 2026-07-24 | NCT06078384 | |
| This Study Aims to Investigate the Efficacy of Photobiomodulation in the Treatment of Anti-MAG-induced Peripheral Neuropathy (LASER-MAG) | Blood Protein Disorders, Hemic and Lymphatic Diseases, hematologic disorder, immune system disorder, immunoproliferative disorder, monoclonal gammopathy, nervous system disorder, neuromuscular disease, peripheral nervous system disorder | Enrolling by invitation | Not stated | 2026-06-22 | NCT07661667 | |
| RItuximab Versus Ocrelizumab in Relapsing-remitting Multiple Sclerosis. | CNS demyelinating autoimmune disease, autoimmune disease, autoimmune disorder of the nervous system, demyelinating disease, immune system disorder, multiple sclerosis, nervous system disorder, relapsing-remitting multiple sclerosis | Recruiting | Phase 3 | 2026-02-02 | NCT05758831 | |
| FIRST-NEC (GFPC 01-2022) - Combination of Durvalumab With Etoposide and Platinum | Neoplasms by Site, Thoracic Neoplasms, lung disorder, lung neoplasm, neoplasm, pulmonary large cell neuroendocrine carcinoma, respiratory system disorder, respiratory tract neoplasm | Recruiting | Phase 2 | 2024-08-02 | NCT06393816 |